Free Trial
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

Verona Pharma plc (VRP.L) logo

About Verona Pharma plc (VRP.L) (LON:VRP)

Key Stats

Today's Range
N/A
50-Day Range
55
55
52-Week Range
N/A
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228 million
Assets Under Management
N/A
Dividend Yield
N/A
Net Expense Ratio
0.00%
Aggregate Rating
N/A

ETF Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

VRP ETF News Headlines

Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
9 hidden AI stocks set to thrive in Trump’s new era
AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)
Verona Pharma Q3 2024 Earnings Preview
Piper Sandler Remains a Buy on Verona Pharma (VRNA)
See More Headlines

VRP ETF - Frequently Asked Questions

Verona Pharma plc (VRP.L) (LON:VRP) issued its earnings results on Thursday, February, 27th. The company reported ($30.30) EPS for the quarter, topping the consensus estimate of ($30.80) by $0.50.

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (LON:VRP) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners